“…According to these considerations, researchers firstly turned their attention to already clinically approved contrast agents, such as iodinated contrast media, exploiting their high safety profile and FDA approval (Aime et al, 2005b;Longo et al, 2011). Consequently, radiographic agents have been exploited for assessing tumor microenvironment properties, including perfusion (Anemone et al, 2017;Longo et al, 2016b), acidosis (Chen et al, 2015;Jones et al, 2015;Longo et al, 2016a;Longo et al, 2014b;Sun et al, 2014) and for assessing renal functionality (Longo et al, 2013;Longo et al, 2017).…”